Co-Pays For GLP-1 Weight Loss Drugs To Rise If They’re Even Covered
Key takeaways
- Healthcare Co-Pays For GLP-1 Weight Loss Drugs To Rise If They’re Even Covered By Bruce Japsen,
- And that’s not good for employee out-of-pocket costs.
- Take last week’s 2026 Milliman Medical Index report showing the annual cost of insuring a family of four eclipsed $35,000, rising 7.2% between 2025 and 2026.
Healthcare Co-Pays For GLP-1 Weight Loss Drugs To Rise If They’re Even Covered By Bruce Japsen,
Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy.Follow Author May 24, 2026, 09:52am EDT--:-- / --:--This voice experience is generated by AI. Learn more.This voice experience is generated by AI. Learn more.Photo Illustration of the new Wegovy semaglutide tablets with injectable prescription weight loss medicines, Ozempic, Victoza and Wegovy. Its a prescription medicine used with a reduced calorie diet and physical activity. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images)UCG/Universal Images Group via Getty ImagesThe latest report on rising employer healthcare costs shows GLP-1 weight loss drugs like Ozempic, Zepbound and Wegovy are the biggest contributors to rising prescription spending.
And that’s not good for employee out-of-pocket costs.